Logo

Corbus Pharmaceuticals Holdings, Inc.

CRBP

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the trea… read more

Healthcare

Biotechnology

11 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$8.92

Price

-0.56%

-$0.05

Market Cap

$165.268m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$84.528m

-7.6%

1y CAGR

-31.0%

3y CAGR

-18.2%

5y CAGR
EPS

-$6.60

-11.9%

1y CAGR

-2.6%

3y CAGR

-2.4%

5y CAGR
Book Value

$126.342m

$144.480m

Assets

$18.138m

Liabilities

$1.205m

Debt
Debt to Assets

0.8%

-

Debt to EBITDA
Free Cash Flow

-$73.654m

-14.2%

1y CAGR

-28.1%

3y CAGR

-20.1%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases